Edmond DE Rothschild Holding S.A. Sells 29,185 Shares of Illumina, Inc. (NASDAQ:ILMN)

Edmond DE Rothschild Holding S.A. reduced its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 10.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 255,186 shares of the life sciences company's stock after selling 29,185 shares during the period. Edmond DE Rothschild Holding S.A. owned about 0.16% of Illumina worth $34,101,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Versant Capital Management Inc grew its holdings in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after purchasing an additional 146 shares during the last quarter. Golden State Wealth Management LLC acquired a new stake in Illumina during the 4th quarter valued at $32,000. Assetmark Inc. raised its stake in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Illumina during the 4th quarter worth approximately $45,000. Finally, Lee Danner & Bass Inc. acquired a new position in shares of Illumina in the 4th quarter valued at $48,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on ILMN shares. Robert W. Baird dropped their price objective on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. Hsbc Global Res downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Barclays restated an "underweight" rating on shares of Illumina in a report on Tuesday, March 11th. Citigroup reduced their price target on shares of Illumina from $130.00 to $90.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Finally, Stephens reaffirmed an "overweight" rating and set a $156.00 price objective on shares of Illumina in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $140.90.

Remove Ads

Illumina Trading Down 3.8 %

NASDAQ ILMN traded down $2.91 on Friday, reaching $73.51. The company had a trading volume of 1,453,736 shares, compared to its average volume of 2,210,510. Illumina, Inc. has a fifty-two week low of $70.68 and a fifty-two week high of $156.66. The business has a 50 day moving average of $98.06 and a two-hundred day moving average of $125.48. The firm has a market cap of $11.64 billion, a price-to-earnings ratio of -9.56, a P/E/G ratio of 1.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.